Meridian Bioscience

64 articles with Meridian Bioscience

• Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

  5/26/2022

  Meridian Bioscience, Inc. announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests.

• Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

  5/23/2022

  Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced its participation in the 2022 H.C. Wainwright Global Investment Conference.

• Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

  5/17/2022

  Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready™ Direct DNA LAMP Saliva Mix and Lyo-Ready™ Direct RNA/DNA LAMP Saliva Mix.

• Meridian Bioscience Reports Record Second Quarter Fiscal 2022 Operating Results

  5/6/2022

  Meridian Bioscience, Inc. announced financial results for the second quarter ended March 31, 2022.

• Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

  5/2/2022

  Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.

• Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

  4/7/2022

  Meridian Bioscience, Inc. today provided preliminary net revenues results for its second quarter of fiscal 2022.

• Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

  3/29/2022

  Meridian Bioscience, Inc. announced today the launch of two new master mixes that detect DNA and RNA in crude blood samples down to a single copy – enabling the earliest detection of cancer using non-invasive liquid biopsy.

• Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

  2/21/2022

  Meridian Bioscience, Inc. announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny.

• Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

  2/16/2022

   Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their LeadCare® II test kits.

• MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

  2/4/2022

  Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021.

• Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

  1/28/2022

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude saliva samples. 

• Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

  1/27/2022

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that John C. McIlwraith has been elected as Chairman of the Meridian Board of Directors, effective January 26, 2022.

• Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

  1/10/2022

   Meridian Bioscience, Inc. will report first quarter 2022 financial results Friday, February 4, 2022.

• Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

  1/5/2022

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food and Drug Administration (FDA) clearance.  

• Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

  12/2/2021

  Meridian Bioscience, Inc. announced today that Bryan Baldasare , Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31 , 2021. 

• Meridian Bioscience Announces Retirement of Chairman David Phillips

  11/24/2021

  Meridian Bioscience, Inc. announced today that David Phillips , Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.

• Meridian Bioscience Participates in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/18/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1st and 2nd, 2021. Jack Kenny, Chief Executive Officer, pre-recorded a fireside chat on Tuesday, November 16, 2021.

• Meridian Bioscience Reports Strong Fourth Quarter And Record Full-Year Fiscal 2021 Operating Results And Provides Fiscal 2022 Guidance

  11/12/2021

   Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021 .

• Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay

  11/10/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene® SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). 

• Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples

  10/27/2021

  Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples.